{"id":56100,"date":"2026-02-03T16:10:12","date_gmt":"2026-02-03T08:10:12","guid":{"rendered":"https:\/\/flcube.com\/?p=56100"},"modified":"2026-02-03T16:10:14","modified_gmt":"2026-02-03T08:10:14","slug":"wuxi-biologics-partners-with-vertex-on-trispecific-t-cell-engager-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56100","title":{"rendered":"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases"},"content":{"rendered":"\n<p><strong>WuXi Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2269:HKG\">HKG:\u202f2269<\/a>) announced a partnership with <strong>Vertex Pharmaceuticals<\/strong> for an innovative <strong>trispecific T\u2011cell engager (TCE)<\/strong> intended for the treatment of B\u2011cell mediated autoimmune diseases. Vertex will obtain <strong>exclusive global rights<\/strong> to develop and commercialize the preclinical\u2011stage asset, while WuXi will receive upfront and milestone payments plus royalties.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-terms\">Deal Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>WuXi Biologics (HKG:\u202f2269) \/ Vertex Pharmaceuticals<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Trispecific T\u2011cell engager (TCE)<\/td><\/tr><tr><td><strong>Stage<\/strong><\/td><td>Preclinical<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>B\u2011cell mediated autoimmune diseases<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Exclusive global development and commercialization (Vertex)<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + development, registration, and sales milestones + royalties<\/td><\/tr><tr><td><strong>Services<\/strong><\/td><td>WuXi provides integrated CRO and development services<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>Expands WuXi\u2019s biologics pipeline and Vertex\u2019s autoimmune portfolio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-technology\">Drug Profile &amp; Technology<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Trispecific T\u2011cell engager designed to redirect T\u2011cells to eliminate pathogenic B\u2011cells in autoimmune disorders<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Multi\u2011targeting approach may offer superior efficacy vs. bispecific antibodies in complex autoimmune diseases<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Leverages WuXi\u2019s antibody discovery and manufacturing capabilities with Vertex\u2019s clinical development expertise<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> B\u2011cell mediated autoimmune diseases include <strong>rheumatoid arthritis, lupus, and multiple sclerosis<\/strong>, representing a <strong>$50\u202fbillion<\/strong> : global market<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China CRO Market:<\/strong> WuXi\u2019s deal reinforces its leadership position in biologics outsourcing, adding high\u2011value TCE platform capabilities<\/li>\n\n\n\n<li><strong>Autoimmune Pipeline:<\/strong> Vertex gains a differentiated preclinical asset to complement its existing <strong>$2\u202fbillion<\/strong> : CF and sickle cell franchise<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>$800\u202fmillion\u20131.2\u202fbillion<\/strong> : peak global sales for the TCE if approved, based on specialty autoimmune pricing<\/li>\n\n\n\n<li><strong>Strategic Validation:<\/strong> Upfront payment validates WuXi\u2019s discovery platform; milestones align incentives for successful development<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> IND\u2011enabling studies expected to commence <strong>Q2\u202f2026<\/strong> ; Vertex to lead global clinical program<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding development timelines, milestone achievements, and commercial prospects for the trispecific TCE. Actual results may differ due to preclinical risks, competitive dynamics, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>WuXi Biologics (HKG:\u202f2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T\u2011cell engager&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,19,952,2790,1074,292],"class_list":["post-56100","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-cro-cmo-cdmo","tag-hkg-2269","tag-t-cell-engager","tag-vertex-pharmaceuticals","tag-wuxi-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi Biologics (HKG:\u202f2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T\u2011cell engager (TCE) intended for the treatment of B\u2011cell mediated autoimmune diseases. Vertex will obtain exclusive global rights to develop and commercialize the preclinical\u2011stage asset, while WuXi will receive upfront and milestone payments plus royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56100\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"WuXi Biologics (HKG:\u202f2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T\u2011cell engager (TCE) intended for the treatment of B\u2011cell mediated autoimmune diseases. Vertex will obtain exclusive global rights to develop and commercialize the preclinical\u2011stage asset, while WuXi will receive upfront and milestone payments plus royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56100\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T08:10:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T08:10:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56100#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56100\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases\",\"datePublished\":\"2026-02-03T08:10:12+00:00\",\"dateModified\":\"2026-02-03T08:10:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56100\"},\"wordCount\":329,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 2269\",\"T cell engager\",\"Vertex Pharmaceuticals\",\"WuXi Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56100#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56100\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56100\",\"name\":\"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-03T08:10:12+00:00\",\"dateModified\":\"2026-02-03T08:10:14+00:00\",\"description\":\"WuXi Biologics (HKG:\u202f2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T\u2011cell engager (TCE) intended for the treatment of B\u2011cell mediated autoimmune diseases. Vertex will obtain exclusive global rights to develop and commercialize the preclinical\u2011stage asset, while WuXi will receive upfront and milestone payments plus royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56100#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56100\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56100#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"WuXi Biologics (HKG:\u202f2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T\u2011cell engager (TCE) intended for the treatment of B\u2011cell mediated autoimmune diseases. Vertex will obtain exclusive global rights to develop and commercialize the preclinical\u2011stage asset, while WuXi will receive upfront and milestone payments plus royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56100","og_locale":"en_US","og_type":"article","og_title":"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases","og_description":"WuXi Biologics (HKG:\u202f2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T\u2011cell engager (TCE) intended for the treatment of B\u2011cell mediated autoimmune diseases. Vertex will obtain exclusive global rights to develop and commercialize the preclinical\u2011stage asset, while WuXi will receive upfront and milestone payments plus royalties.","og_url":"https:\/\/flcube.com\/?p=56100","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-03T08:10:12+00:00","article_modified_time":"2026-02-03T08:10:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56100#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56100"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases","datePublished":"2026-02-03T08:10:12+00:00","dateModified":"2026-02-03T08:10:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56100"},"wordCount":329,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","CRO \/ CMO \/ CDMO","HKG: 2269","T cell engager","Vertex Pharmaceuticals","WuXi Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56100#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56100","url":"https:\/\/flcube.com\/?p=56100","name":"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-03T08:10:12+00:00","dateModified":"2026-02-03T08:10:14+00:00","description":"WuXi Biologics (HKG:\u202f2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T\u2011cell engager (TCE) intended for the treatment of B\u2011cell mediated autoimmune diseases. Vertex will obtain exclusive global rights to develop and commercialize the preclinical\u2011stage asset, while WuXi will receive upfront and milestone payments plus royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56100#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56100"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56100#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56100"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56100\/revisions"}],"predecessor-version":[{"id":56132,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56100\/revisions\/56132"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}